MCID: OLG006
MIFTS: 38

Oligoastrocytoma

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Oligoastrocytoma

MalaCards integrated aliases for Oligoastrocytoma:

Name: Oligoastrocytoma 54 60 30 17
Mixed Oligoastrocytoma 60 74
Mixed Oligodendroglioma-Astrocytoma 74
Oligoastrocytoma Mixed 56
Moa 60

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 35 C71.9
UMLS via Orphanet 75 C0280793
Orphanet 60 ORPHA251656

Summaries for Oligoastrocytoma

NIH Rare Diseases : 54 Oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass.  These brain cells are known as glial cells, which normally protect and support nerve cells in the brain.  Because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma.  Oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50.  The exact cause of this condition is unknown.

MalaCards based summary : Oligoastrocytoma, also known as mixed oligoastrocytoma, is related to oligodendroglioma and anaplastic oligodendroglioma, and has symptoms including seizures and headache. An important gene associated with Oligoastrocytoma is GFAP (Glial Fibrillary Acidic Protein). The drugs Carmustine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone.

Wikipedia : 77 Oligoastrocytomas are a subset of brain tumors that present with an appearance of mixed glial cell... more...

Related Diseases for Oligoastrocytoma

Diseases related to Oligoastrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 oligodendroglioma 30.2 GFAP IDH2 MGMT
2 anaplastic oligodendroglioma 29.9 GFAP IDH2 MGMT
3 glioblastoma 29.5 IDH2 MGMT
4 grade iii astrocytoma 29.4 GFAP IDH2 MGMT
5 medulloblastoma 29.3 GFAP MGMT
6 anaplastic oligoastrocytoma 12.7
7 astrocytoma 10.4
8 glioma 10.2
9 leukemia 10.1
10 mixed glioma 10.1
11 pleomorphic xanthoastrocytoma 9.9 GFAP MGMT
12 multiple sclerosis 9.9
13 mismatch repair cancer syndrome 9.9
14 leukemia, acute myeloid 9.9
15 leukemia, acute lymphoblastic 9.9
16 focal dystonia 9.9
17 myelomeningocele 9.9
18 cysticercosis 9.9
19 dermatomyositis 9.9
20 lymphocytic leukemia 9.9
21 status epilepticus 9.9
22 epilepsy 9.9
23 myelitis 9.9
24 dystonia 9.9
25 paraplegia 9.9
26 myeloid leukemia 9.9
27 cerebrospinal fluid leak 9.9
28 opsoclonus-myoclonus syndrome 9.9
29 transverse myelitis 9.9
30 myoclonus 9.9
31 spinal cord astrocytoma 9.9 GFAP MGMT
32 brain glioma 9.9 GFAP MGMT
33 giant cell glioblastoma 9.9 GFAP MGMT
34 ependymoma 9.9 GFAP MGMT
35 gliosarcoma 9.8 GFAP MGMT
36 glioblastoma multiforme 9.8 GFAP MGMT
37 gemistocytic astrocytoma 9.8 GFAP IDH2
38 protoplasmic astrocytoma 9.8 GFAP IDH2
39 glioma susceptibility 1 9.8 GFAP IDH2
40 large intestine cancer 9.6 IDH2 MGMT
41 fibrillary astrocytoma 9.5 GFAP IDH2 MGMT
42 supratentorial cancer 9.5 GFAP IDH2 MGMT
43 cerebrum cancer 9.5 GFAP IDH2 MGMT
44 central nervous system cancer 9.5 GFAP IDH2 MGMT
45 nervous system cancer 9.5 GFAP IDH2 MGMT
46 brain cancer 9.5 GFAP IDH2 MGMT

Graphical network of the top 20 diseases related to Oligoastrocytoma:



Diseases related to Oligoastrocytoma

Symptoms & Phenotypes for Oligoastrocytoma

UMLS symptoms related to Oligoastrocytoma:


seizures, headache

Drugs & Therapeutics for Oligoastrocytoma

Drugs for Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Not Applicable 154-93-8 2578
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
6
tannic acid Approved Phase 3 1401-55-4
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
11 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
12 Dermatologic Agents Phase 3,Phase 1,Phase 2
13 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Early Phase 1
14 Antiviral Agents Phase 3,Phase 1,Early Phase 1
15 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
16 interferons Phase 3,Phase 1,Early Phase 1
17 Gastrointestinal Agents Phase 3,Phase 1,Early Phase 1,Not Applicable
18 Interferon alpha-2 Phase 3
19 Interferon-alpha Phase 3
20 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
21 Histamine Antagonists Phase 3
22 Serotonin Agents Phase 3
23 Serotonin Antagonists Phase 3
24 Anti-Allergic Agents Phase 3
25 Antipruritics Phase 3
26 Histamine H1 Antagonists Phase 3
27
Histamine Phosphate Phase 3 51-74-1 65513
28
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
29
Iodine Approved, Investigational Phase 2 7553-56-2 807
30
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
31
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
32
Lenograstim Approved, Investigational Phase 2 135968-09-1
33
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
34
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
35
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
36
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
37
Hydroxyurea Approved Phase 2 127-07-1 3657
38
Nintedanib Approved Phase 2 656247-17-5 56843413
39
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
40
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
41
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
42
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
43
Palbociclib Approved, Investigational Phase 2,Phase 1 571190-30-2 5005498 11431660 5330286
44
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
45
Mannitol Approved, Investigational Phase 1, Phase 2,Phase 2 69-65-8 6251 453
46
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
47
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
48
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
49
Dopamine Approved Phase 2,Not Applicable 62-31-7, 51-61-6 681
50
Vorinostat Approved, Investigational Phase 1, Phase 2,Phase 2 149647-78-9 5311

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
3 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
4 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
5 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
6 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
9 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
10 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
11 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
12 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
13 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
14 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
15 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
16 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
17 Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma Completed NCT00041587 Phase 1, Phase 2 IL13-PE38QQR
18 Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma Completed NCT00024570 Phase 1, Phase 2 IL13-PE38QQR
19 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
20 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2 Bevacizumab
21 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
22 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
23 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
24 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
25 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
26 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Recruiting NCT02530320 Phase 2 Palbociclib
27 Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
28 Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
29 Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Recruiting NCT03180502 Phase 2 Temozolomide
30 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
31 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Active, not recruiting NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
32 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Active, not recruiting NCT02209428 Phase 2 Temozolomide
33 Everolimus With and Without Temozolomide in Adult Low Grade Glioma Active, not recruiting NCT02023905 Phase 2 Everolimus;Temozolomide
34 A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas Active, not recruiting NCT02104310 Phase 2 Fluorine-18-L-dihydroxyphenylalanine
35 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Active, not recruiting NCT01635283 Phase 2
36 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
37 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
38 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
39 A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas Active, not recruiting NCT01986348 Phase 2 Selinexor
40 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
41 Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas Terminated NCT00062504 Phase 2 Talampanel
42 Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors Terminated NCT00848523 Phase 2 Panobinostat
43 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Terminated NCT01110876 Phase 1, Phase 2 Vorinostat;Erlotinib;Temozolomide
44 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma Withdrawn NCT02977689 Phase 2 IDH305
45 Phase I/II Cabazitaxel for Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2 Cabazitaxel
46 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
47 Sorafenib in Newly Diagnosed High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation
48 A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas Completed NCT00526812 Phase 1 RTA 744;RTA 744 injection
49 IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma Completed NCT00089427 Phase 1 IL13-PE38QQR;Temozolomide with radiation therapy
50 A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas Completed NCT00734682 Phase 1 Nanoliposomal CPT-11

Search NIH Clinical Center for Oligoastrocytoma

Genetic Tests for Oligoastrocytoma

Genetic tests related to Oligoastrocytoma:

# Genetic test Affiliating Genes
1 Oligoastrocytoma 30

Anatomical Context for Oligoastrocytoma

MalaCards organs/tissues related to Oligoastrocytoma:

42
Brain, Testes, Bone, Myeloid, Spinal Cord, Bone Marrow

Publications for Oligoastrocytoma

Articles related to Oligoastrocytoma:

(show top 50) (show all 80)
# Title Authors Year
1
Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus. ( 30462564 )
2019
2
Neurosurgical therapy for Status Epilepticus in Oligoastrocytoma Patient: A case report. ( 30682510 )
2019
3
Extracranial metastasis of anaplastic oligoastrocytoma. ( 30197798 )
2018
4
Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma. ( 30601146 )
2018
5
Increased HSPG2 expression independently predicts poor survival in patients with oligoastrocytoma and oligodendroglioma. ( 30402850 )
2018
6
Focal seizure induced by preoperative navigated transcranial magnetic stimulation in a patient with anaplastic oligoastrocytoma. ( 28017645 )
2017
7
Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity? ( 28419269 )
2017
8
Multifocal and multicentric low-grade oligoastrocytoma in a young patient. ( 28523320 )
2017
9
Primary spinal cord anaplastic oligoastrocytoma presenting with paraplegia. ( 26851716 )
2016
10
A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. ( 27329275 )
2016
11
Neurosurgery concepts: Key perspectives on intrathecal fluorescein for detecting intraoperative cerebrospinal fluid leak during endoscopic endonasal surgery, spinal intraarterial chemotherapy, oligoastrocytoma classification by in situ molecular genetics, and prenatal myelomeningocele closure and the need for cerebrospinal fluid shunt placement. ( 27857862 )
2016
12
Does morphological assessment have a role in classifying oligoastrocytoma as 'oligodendroglial' versus 'astrocytic'? ( 26466141 )
2016
13
Reply: Does morphological assessment have a role in classifying oligoastrocytoma as 'oligodendroglial' versus 'astrocytic'? Or - who's afraid of the … liger? ( 26598389 )
2016
14
A rare case of oligoastrocytoma with atypical symptoms initially diagnosed as multiple sclerosis: A case report. ( 26893863 )
2016
15
Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery. ( 26995546 )
2016
16
Primary Spinal Oligoastrocytoma. ( 27092919 )
2016
17
Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase. ( 27672647 )
2016
18
Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12. ( 25391968 )
2015
19
Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate? ( 25555564 )
2015
20
Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma. ( 25864100 )
2015
21
Solitary "aggressive" leptomeningeal anaplastic oligoastrocytoma. ( 26318905 )
2015
22
Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"? ( 25359109 )
2015
23
Primary spinal oligoastrocytoma mimicking longitudinally extensive transverse myelitis. ( 26590667 )
2015
24
Farewell to oligoastrocytoma: response to letters. ( 25381649 )
2015
25
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. ( 24162809 )
2014
26
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). ( 24812135 )
2014
27
Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. ( 25489269 )
2014
28
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
29
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. ( 25143301 )
2014
30
Mixed Glioma (Oligoastrocytoma) in the brain of an African Hedgehog (Atelerix albiventris). ( 25172052 )
2014
31
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. ( 23896377 )
2013
32
Infratentorial low-grade oligoastrocytoma with aggressive clinical behavior in an adult: a case report with genetic characterization. ( 22752622 )
2013
33
Analysis of CIC-associated CpG island methylation in oligoastrocytoma. ( 23521081 )
2013
34
Experiential auditory hallucinations due to chronic epileptic discharges after radiotherapy for oligoastrocytoma. ( 23774105 )
2013
35
Cerebellar low-grade oligoastrocytoma presenting with subarachnoid haemorrhage. ( 22665014 )
2012
36
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. ( 20556480 )
2011
37
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. ( 19876600 )
2010
38
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-. ( 20505301 )
2010
39
Anaplastic oligoastrocytoma in Turcot syndrome. ( 19495563 )
2009
40
Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. ( 19225409 )
2009
41
Oligoastrocytoma of the brain in a hooded crane (Grus monacha). ( 19261644 )
2009
42
Multi-focal cerebral oligoastrocytoma in a puppy. ( 19689673 )
2009
43
A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. ( 18317968 )
2008
44
Autoimmunity manifesting as dermatomyositis associated with oligoastrocytoma and dendritic cell immunotherapy. ( 18443006 )
2008
45
Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia. ( 17043901 )
2007
46
Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. ( 17431544 )
2007
47
Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. ( 17660801 )
2007
48
Anaplastic oligodendroglioma and oligoastrocytoma. ( 17964027 )
2007
49
Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. ( 18077983 )
2007
50
Intradural extramedullary spinal spread of oligoastrocytoma. ( 17582770 )
2007

Variations for Oligoastrocytoma

Expression for Oligoastrocytoma

Search GEO for disease gene expression data for Oligoastrocytoma.

Pathways for Oligoastrocytoma

GO Terms for Oligoastrocytoma

Sources for Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....